Search results
Results from the WOW.Com Content Network
Desnitazene (1-diethylaminoethyl-2-benzyl-benzimidazole) hydrogen 0.1 28787: 17817-67-3 Metodesnitazene (Metazene) 4-methoxy 1 26412: 14030-77-4 1071546-40-1 (HCl) Metodesnitazepyne: 4-methoxy Etodesnitazene (Etazene) 4-ethoxy 70 149797386: 14030-76-3 Etodesnitazepyne: 4-ethoxy 20 162623599: Etodesnitazepipne: 4-ethoxy 10 162623611: 102762-98-1 ...
Etonitazene, also known as EA-4941 or CS-4640, [2] is a benzimidazole opioid, first reported in 1957, [3] that has been shown to have approximately 1,000 to 1,500 times the potency of morphine in animals.
Methylenedioxynitazene (3',4'-Methylenedioxynitazene) is a benzimidazole derivative which has been sold as a designer drug over the internet and presumably has opioid effects. It is an analogue of etonitazene where the benzyl ring is substituted with a 3,4-methylenedioxy ring system rather than an ethoxy group.
Benzimidazole is a base: C 6 H 4 N(NH)CH + H + → [C 6 H 4 (NH) 2 CH] + It can also be deprotonated with stronger bases: C 6 H 4 N(NH)CH + LiH → Li [C 6 H 4 N 2 CH] + H 2. The imine can be alkylated and also serves as a ligand in coordination chemistry. The most prominent benzimidazole complex features N-ribosyl-dimethylbenzimidazole, as ...
Etonitazene 5-acetyl analogue (Etoacetazene, 5-acetyldesnitroetonitazene) is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene.
Etonitazene 5-cyano analogue (Etocyanazene, 5-cyanodesnitroetonitazene) is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is an analogue of etonitazene where the 5-nitro (NO 2) group has been replaced by a nitrile (C≡N) group. [1]
Butonitazene is a benzimidazole derivative with opioid effects, which has been sold over the internet as a designer drug.It has relatively low potency compared to many related compounds, and has generally been encountered as a component of mixtures with other substances rather than in its pure form.
They may have been developed sometime between 1950 and 1990. They have similar lethal dose levels to VX (between 10 and 50 mg) and have similar symptoms and method of action to other nerve agents that act on cholinesterase. The treatment remains the same, but the window for effectively treating second generation V series seizures is shorter.